Loading...
Loading...
TAKEDA PHARMACEUTICAL CO LTD
TAKEDA PHARMACEUTICAL CO LTD. Spoken Alpha tracks TAK's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TAK's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TAK.
curl https://api.spokenalpha.com/v1/companies/TAK| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.98 | $4.28 | +39.7% | -3.4% | -1.3% |
| Q4 FY2026 | $5.98 | $4.29 | +39.4% | -6.8% | -8.7% |
| Q3 FY2026 | $5.95 | $4.16 | +43.1% | -4.5% | -6.5% |
| Q2 FY2026 | $6.15 | $4.41 | +39.5% | +3.7% | +2.1% |
| Q1 FY2025 | $6.37 | $4.35 | +46.4% | -4.8% | -6.9% |
| Q4 FY2025 | $6.03 | $4.26 | +41.6% | +1.6% | +0.2% |
| Q3 FY2025 | $6.09 | $4.37 | +39.4% | +4.3% | +3.6% |
| Q2 FY2025 | $6.63 | $4.47 | +48.4% | +2.3% | +2.7% |
| Q1 FY2024 | $6.00 | $4.39 | +36.6% | -0.3% | +2.2% |
| Q4 FY2024 | $6.29 | $4.40 | +42.9% | -3.5% | -2.9% |